Corporate Profile

Absci is the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Stock information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

23 11 / 2022
VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Berenberg Discover AI Seminar in New York, NY. Absci management is scheduled to participate in
17 11 / 2022
VANCOUVER, Wash. and NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.
09 11 / 2022
Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today

Upcoming Events